Intel stock spikes after report of possible US government stake
In a turbulent market environment, Maxpro Capital Acquisition Corp. (APLM) stock has recorded a new 52-week low, dipping to $6.38. According to InvestingPro analysis, the company maintains a current ratio of 2.25, indicating strong short-term liquidity despite market challenges. This latest price level reflects a significant downturn for the company, which has seen its stock value plummet by an alarming 90% over the past year. Investors have been closely monitoring APLM’s performance, as the company grapples with the pressures that have pushed its shares to the lowest point in the last twelve months. InvestingPro data reveals the company is quickly burning through cash, with a weak overall Financial Health Score of 1.29. Subscribers can access 12 additional ProTips and comprehensive financial metrics on the platform. The stark 1-year change data underscores the challenges faced by Maxpro Capital Acquisition, as market participants weigh the potential for recovery against a backdrop of ongoing economic uncertainty. While current market pricing suggests the stock may be undervalued based on InvestingPro’s Fair Value analysis, the company’s negative EBITDA of -$53.1M highlights ongoing operational challenges.
In other recent news, Apollomics Inc., a biopharmaceutical company, has announced disappointing results from its Phase 3 bridging trial of uproleselan in China. The trial, involving patients with relapsed or refractory acute myeloid leukemia, failed to meet its primary endpoint of demonstrating a favorable benefit. Despite the drug being well-tolerated, the company is concluding the uproleselan program due to these results.
In another development, Apollomics has initiated a 1-for-100 reverse share split of its class A ordinary shares, a decision approved by shareholders. This strategic move is intended to adjust the number of shares outstanding, a common practice among public companies.
These are among the recent developments for Apollomics. The company’s lead program is now vebreltinib (APL-101), a c-Met inhibitor currently in a Phase 2 multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. The company anticipates future expenses for the concluded uproleselan program to be under $500,000 and plans to present the full trial results at a future medical conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.